Navigation Links
Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results
Date:9/30/2010

ny related expenses that were incurred in the same quarter.

Operating income decreased 17.1% to $14.7 million, as compared to $17.7 million in the same period of fiscal year 2009. Operating margin as a percentage of revenue decreased to 50.1% from 56.8% in the same period of fiscal year 2009.

Other expenses, comprised primarily of interest expenses, amortization expenses on convertible debentures, and change in fair value of derivative liabilities, were $3.2 million compared to $1.5 million for the three months ended June 30, 2009. Interest expense increased 140.5% to $4.2 million in the fourth quarter of fiscal year 2010, compared to $1.8 million in the year ago period, as a result of additional penalty interest incurred due to the Company's delinquency in paying interest to its convertible debenture holders and its convertible note holders, and significantly increased amortization expenses related to write off of unamortized debt discount as convertible notes were converted into the Company's common shares.

The provision for income taxes was $4.3 million in the fourth quarter of fiscal year 2010, compared to $4.7 million for the three months ended June 30, 2009.

Net income decreased 37.5% to $7.2 million from $11.5 million in the prior year's comparable period, representing basic earnings per share of $0.62. Diluted earnings per share for the fourth quarter of fiscal year 2010 were $(0.39).

Excluding the impact of a loss from discontinued operations of approximately $43,023, an unrealized loss on investments of $0.1 million, a gain in fair value of derivative liabilities of $1.1 million, and amortization of debt discount and issuance costs related to convertible debentures of $3.5 million, non-GAAP adjusted net income for the fourth quarter of fiscal year 2010 was $9.8 million, or $0.85 per basic share, as compared to $12.1 million, or
'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Jiangbo Pharmaceuticals Chairman to Ring NASDAQ Opening Bell on August 27, 2010
2. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
3. Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
4. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
5. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
6. Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010
7. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
8. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
9. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
10. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
11. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... CHICAGO , Ill. and PALO ALTO, ... ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a ... the cystic fibrosis (CF) community through the CFChef Shares ... September 15, 2014, as part of AbbVie,s CFChef program ... – to encourage patients to maintain a healthy diet ...
(Date:8/1/2014)... Aug. 1, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... pivotal Phase 3 study evaluating ISIS-SMN Rx in ... genetic cause of infant mortality. Isis plans to dose ... few weeks, at which time Isis will earn an ... Idec. The Phase 3 study, ENDEAR, is the first ...
(Date:8/1/2014)... Aug. 1, 2014 Arena Pharmaceuticals, Inc. ... corporate update and reported financial results for the ... "We have continued to see encouraging advancements ... 43% quarter-over-quarter increase in estimated total prescriptions and ... mark," said Jack Lief, Arena,s President and Chief ...
Breaking Medicine Technology:AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11
... Ala., May 7 BioCryst Pharmaceuticals (Nasdaq: BCRX ... first quarter 2009 financial results will be released on Friday, ... a conference call and Web cast at 8:30 a.m. Eastern ... on the Company,s programs. The call will be led ...
... The Abbott RealTi m e HIV-1 Assay and Abbott ... protocol for viral load testing in HIV/AIDS clinical trials sponsored ... This recommendation was made by the Cross-Network Laboratory Focus Group ... HIV/AIDS clinical trials networks. The LFG recently issued a consensus ...
Cached Medicine Technology:BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009 2HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials 2HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials 3
(Date:8/1/2014)... University of California, San Diego School of Medicine report ... peppers produces chronic activation of a receptor on ... that ultimately reduces the risk of colorectal tumors. , ... issue of The Journal of Clinical Investigation . ... originally discovered in sensory neurons, where it acts as ...
(Date:8/1/2014)... Barbara Bronson Gray HealthDay Reporter ... and work in manufacturing jobs may have significantly less endurance than ... study of 32 people -- half were obese, half were of ... that were about 60 percent longer. Obesity also was associated ... Being older -- 50 to 65 years of age ...
(Date:8/1/2014)... In a first-of-its-kind study, researchers at University Hospitals Rainbow ... infants may be at greater risk for death on ... emergencies on flights worldwide between January 2010 and June ... children under the age of 2. , The ... the rare event of an in-flight pediatric fatality onboard ...
(Date:8/1/2014)... As AndroGel lawsuits and testosterone lawsuits ... Johnson, Jr. has been appointed as co-lead counsel to ... medications. Since the Fall of 2013, Ron and his ... to investigate and prosecute the claims of men who ... as a result of taking testosterone. As a result ...
(Date:8/1/2014)... Growing prevalence of chronic ailments, ... are boosting healthcare market growth, although a reduction ... increasing generic consumption is a major challenge. , ... 2013, having grown at a Compound Annual Growth ... of the Health Transformation Program (Saglikta Donus, um ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:New research characterizes in-flight pediatric deaths 2Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4
... PHILADELPHIA Scientists believe they have identified a role for ... from UVB radiation, a known risk factor for non-melanoma skin ... , a journal of the American Association for Cancer Research. ... at the University of Chicago, found that laboratory mice with ...
... School of Public Health (HSPH) has been awarded a ... Gates Foundation to test the effectiveness of an innovative ... outcomes of mothers and infants in 120 hospitals in ... Organization (WHO) and HSPH. Atul Gawande, associate professor in ...
... 2011 Adding hormone therapy to radiation therapy has ... survival for men with intermediate- and high-risk prostate cancer. ... men with pre-existing heart conditions, even if they have ... published online in advance of print in the ...
... for returning veterans may include addictions, injury and the ... a University of Houston joint study funded by the ... to address these issues through the use of virtual ... Work (GCSW) joins Baylor College of Medicine and the ...
... People who abused methamphetamine or other amphetamine-like stimulants were ... did not, in a new study from the Centre ... examined almost 300,000 hospital records from California covering 16 ... disorders had a 76 per cent higher risk of ...
... ROCKVILLE, MD, USA/BEIJING, CHINA, July 26, 2011 Aeras and ... of a memorandum of understanding for the organizations to pursue ... potentially other parts of the world. The partnership ... development of TB vaccines. TB is a major public ...
Cached Medicine News:Health News:Harvard School of Public Health receives $14.1 million to test childbirth checklist 2Health News:Harvard School of Public Health receives $14.1 million to test childbirth checklist 3Health News:Hormone therapy may be hazardous for men with heart conditions 2Health News:Returning vets' alcohol abuse addressed in virtual reality study 2Health News:Increased risk of Parkinson's disease in methamphetamine users, CAMH study finds 2Health News:Aeras and China National Biotech Group sign memorandum of understanding for TB vaccine R&D 2
... stapler is a full-feature skin stapler with ... RH has improved visibility over existing fixed-head ... mechanism for easier staple placement., ,This ... use instrument designed to deliver rectangular, stainless ...
... linear stapler with LACTOMER™ 9-1 ... is a copolymer of glycolide ... Suture™ ROTICULATOR 55 POLY™ single ... use in abdominal, gynecologic, pediatric ...
... Loading Units With Titanium Staples ... TA™ (Single Use Reloadable Stapler ... Auto Suture™ PREMIUM MULTIFIRE TA™ ... gynecological, pediatric and thoracic surgical ...
... reloadable linear stapler for resection, transection and ... Suture™ MULTIFIRE GIA™ 60 and 80 single ... and 80 single use loading units and ... single use surgical stapler with MULTIFIRE SGIA™ ...
Medicine Products: